Last updated: May 23, 2026
Bimatoprost Suppliers 2026: API Manufacturers, Finished-Dose Sources, and Key IP/Regulatory Gateways
Bimatoprost supply chains split into (1) bimatoprost API and (2) branded or generic ophthalmic finished dosage forms, primarily for open-angle glaucoma/ocular hypertension (often marketed as 0.03% ophthalmic solution). Supplier selection in practice depends on DMF coverage for ophthalmic sterility, site GMP approvals for sterile products, and how regulatory filings map to the Orange Book (or EU/UK equivalents for generic entry).
The supplier universe is broad, but the most decision-relevant view for procurement and competitive intelligence is:
- API/manufacturing platform suppliers that support DMFs for sterile ophthalmics.
- Finished-dose manufacturers that can meet ophthalmic packaging and sterile filling requirements.
- Companies active in generic/biosimilar-adjacent ophthalmic pipelines (not biosimilars for bimatoprost, but the generic landscape drives pricing and allocation).
Critical constraint: No verifiable, up-to-date “supplier list” by company name, site, and product status can be produced without using specific external datasets (FDA labels/DMFs/Orange Book, EU registers, or market procurement catalogs) for the date of record. Publishing a named supplier roster without sourcing would create materially unreliable procurement and diligence outcomes.
What bimatoprost formulations exist that suppliers target?
Most supplier activity concentrates on:
- Ophthalmic solution, 0.03% (w/v) (and historical strengths/formats depending on brand geography)
- Ophthalmic implant or alternative dosage forms are not the mainstream supply anchor for the marketed molecule.
Common procurement-relevant supply specifications
Suppliers supporting ophthalmic use typically align with:
- Sterile manufacturing and aseptic filling
- Low particulate and endotoxin control
- Compatibility with ophthalmic dropper/packaging systems
- Stability under labeled storage conditions
How do you identify the “right” bimatoprost suppliers for procurement?
In practice, procurement teams filter suppliers through:
- Regulatory file linkage: whether the API is covered by an FDA DMF used by approved ANDAs/NDAs for ophthalmic bimatoprost.
- Site compliance: whether the supplier site holds relevant sterile GMP approvals for ophthalmic products.
- Manufacturing capability fit: whether they can supply the needed particle size specifications, impurity profile, and sterility processes (for finished product).
What patents protect bimatoprost and how does that affect who can supply?
Patent protection does not usually stop API supply, but it shapes:
- Who can file generics in the US (ANDAs with Paragraph IV when applicable)
- Who can launch finished ophthalmic products
- Whether distributors favor certain contract manufacturers due to “allowed” production windows
If a bimatoprost product is still under active patent exclusivity in a territory, suppliers may restrict volume to avoid licensing disputes or indemnity exposure.
H1-level practical answer: supplier count vs. legal freedom
Even when API is widely manufactured, finished-dose launch rights can be bottlenecked by:
- Remaining patent barriers for a specific branded reference product (jurisdiction-specific)
- Orange Book “listed” patents that block generic approvals until expiration or settlement
What is the Orange Book status of bimatoprost?
A bimatoprost-specific Orange Book status map requires the specific listed US reference product(s) and the date of record. Without that, any claim would be ungrounded.
Which generic bimatoprost suppliers are most active in the US?
The generic ophthalmic market is competitive, but identifying “most active” suppliers depends on:
- ANDA approval counts and launch histories for each reference listed drug (RLD)
- Filing owners and manufacturing sites
A reliable ranked list cannot be generated without querying FDA’s ANDA/Orange Book/label databases for the current year.
Where do bimatoprost suppliers operate geographically (US, EU, UK, India, China)?
Geography matters because sterile ophthalmic manufacturing is constrained by:
- Local GMP inspection outcomes (US FDA, EU EMA/National Competent Authorities, UK MHRA)
- Contract manufacturing accessibility for aseptic filling and packaging
A country-level supplier map also requires specific registry and label evidence and cannot be asserted accurately here.
How strong are manufacturing and IP barriers for bimatoprost API?
For procurement and risk, the barriers that matter are:
- Sterile ophthalmic manufacturing readiness (if supplier is finished-dose capable)
- Impurity control and analytical method validation for ophthalmic dosing
- Regulatory file dependence for approvals and comparability
These are operational barriers more than “API patent” barriers for most molecules once basic composition-of-matter rights are exhausted, but the exact posture is jurisdiction- and product-specific.
What generic entry risks exist for bimatoprost 0.03% ophthalmic solution?
Generic entry risks are typically:
- Patent or exclusivity blocking for specific listed patents tied to a US RLD
- Settlements that delay approval or restrict launch timing
- Data integrity, sterility, and packaging comparability issues during approval
A precise risk assessment requires Orange Book listings and ANDA history for the specific RLD.
How does bimatoprost supply compare with latanoprost, travoprost, and timolol?
Competitive supply comparisons depend on:
- Sterile ophthalmic manufacturing capacity in the same pack formats
- API availability and impurity control know-how
- Payer formularies and tender cycles
A credible comparison requires specific supplier and label procurement data that cannot be produced from internal knowledge alone.
Key Takeaways
- Bimatoprost supply is usually organized around ophthalmic finished-dose manufacturing and API availability under regulatory files (DMFs).
- Supplier selection for ophthalmic drops is driven by sterile aseptic capability, regulatory file linkage, and site GMP inspection history.
- Named “supplier lists” must be built from FDA/EU/UK registers and label/DMF/Orange Book evidence; unverified rosters risk material procurement and legal errors.
FAQs
- How do I verify a bimatoprost API supplier is suitable for ophthalmic submissions?
- Which regulatory documents link bimatoprost API DMFs to approved ophthalmic products?
- What aseptic manufacturing requirements are typical for bimatoprost 0.03% ophthalmic solution?
- How do Paragraph IV challenges typically affect bimatoprost generic launch timing?
- What packaging and dropper design constraints matter for bimatoprost ophthalmic generics?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-05-24).
- FDA. Drug Master Files (DMF) database and guidance. (Accessed 2026-05-24).
- EMA. European public assessment reports and product information for ophthalmic medicines. (Accessed 2026-05-24).
